Company Makes Rapid Testing Solutions Available to Remote Areas of
Colombia and Several Other New Countries
HALIFAX, Feb. 5, 2014 /CNW/ - MedMira Inc.(TSXV: MIR) and its Multiplo™ Rapid TP/HIV rapid test for syphilis and HIV have
enabled the success of a humanitarian project led by the Colombian
National Navy. Multiplo™ Rapid TP/HIV Antibody Test was used in a
project to save the lives of unborn babies in remote areas of
Colombia. This is just one example, among many of MedMira's expansion
into Latin America and the company's growing customer base in this
market. The company has recently earned several key product approvals,
established new distribution agreements and made shipments of its
products built on its patented and versatile Rapid Vertical Flow
Technology™. This technology makes high quality, cost-effective rapid
testing solutions possible, in even the most remote locations.
As part of its ongoing humanitarian efforts, the Colombian National Navy
has implemented a new program called Expectant Family, which promotes
the testing of sexually transmitted diseases in pregnant women living
in remote areas where access to healthcare and laboratory testing is
limited. The National Navy is using MedMira's Multiplo TP/HIV test to
screen women at least twice during the pregnancy, before the third
month and prior to giving birth, for syphilis and HIV.
"In the remote areas of Columbia where healthcare services and
laboratory testing is scarce, pregnant women do not have access to life
saving tests that could easily prevent mother-to-child transmission and
neonatal deaths," said Dr. Liliana Lora Sierra, Public Health Support
Professional, Colombian National Navy. "Working with MedMira, we are
able to offer these women high quality, rapid tests that will help
prevent vertical transmission of TP/HIV that could not only save their
lives but the lives of their unborn children. The test is very easy to
perform and does not require any special training allowing us to screen
patients at the point-of-care. Without MedMira's innovative technology,
these women would not have access to tests that those living in urban
areas benefit from."
In addition to the work in Columbia, MedMira has signed a distribution
deal in Venezuela for the Company's Reveal® Rapid HIV Antibody Test.
The deal is to provide tests to the private healthcare sector, which
serves more than half of all patients and last week the company made
the initial shipment to its partners in Venezuela. MedMira has also
received approval to market the Reveal HIV test in Costa Rica and has
registrations and evaluations for both Reveal and Multiplo product
ranges underway in other Latin American countries including Panama,
Mexico, Ecuador, Brazil and Argentina. The company continues to
leverage its partnership with the Pan American Health Organization
(PAHO) having recently received new orders from the National HIV & TB
program for the Ministry of Health in Belize.
The company has steadily increased its shipments to Latin America, over
the last 12 months, due to the rising demand for cost effective, fast
and of high quality products. In addition, the global need for tests
that can simultaneously detect multiple markers has highlighted one of
the key advantages of MedMira's patented Vertical Flow Technologyä
against its competitors, which is the ability to multiplex assays on
one device. This enables MedMira to reach a much broader market by
attracting partners and customers in the private healthcare, research,
and life sciences sectors.
About MedMira
MedMira is a leading developer and manufacturer of vertical flow rapid
diagnostics. The Company's tests provide hospitals, labs, clinics and
individuals with instant diagnosis for diseases such as HIV and
hepatitis C in just three easy steps. The Company's tests are sold
under the Reveal, Multiplo and Miriad™ brands in global markets. Based
on its patented Rapid Vertical Flow Technology, MedMira's rapid HIV
test is the only one in the world to achieve regulatory approvals in
Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in Halifax,
Nova Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
approval and launch of new products, future growth, and new business
opportunities. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE MedMira Inc.
<p> </p> <p> MedMira Contact:<br/> Andrea Young, Corporate Communications<br/> T. 902-450-1588<br/> E. <a href="mailto:ayoung@medmira.com">ayoung@medmira.com</a><br/> Chempetitive Group for MedMira:<br/> Rachel Lear<br/> T. 781-775-3640<br/> E. <a href="mailto:MedMira@Chempetitive.com">MedMira@Chempetitive.com</a> </p>